Cargando…
Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort
PURPOSE: Trastuzumab-emtansine (T-DM1), as well as lapatinib plus capecitabine were proven effective in two Phase III studies, following first-line trastuzumab plus a taxane. The introduction of dual HER2 blockade by trastuzumab and pertuzumab as first-line has positioned T-DM1 into second-line, and...
Autores principales: | Moinard-Butot, Fabien, Saint-Martin, Caroline, Pflumio, Carole, Carton, Matthieu, Jacot, William, Cottu, Paul-Henri, Diéras, Véronique, Dalenc, Florence, Goncalves, Anthony, Debled, Marc, Patsouris, Anne, Mouret-Reynier, Marie-Ange, Vanlemmens, Laurence, Leheurteur, Marianne, Emile, George, Ferrero, Jean-Marc, Desmoulins, Isabelle, Uwer, Lionel, Eymard, Jean-Christophe, Cheaib, Bianca, Courtinard, Coralie, Bachelot, Thomas, Chevrot, Michaël, Petit, Thierry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927850/ https://www.ncbi.nlm.nih.gov/pubmed/35299035 http://dx.doi.org/10.1016/j.breast.2022.03.004 |
Ejemplares similares
-
Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation
por: Yamashita-Kashima, Yoriko, et al.
Publicado: (2020) -
Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results
por: Ocaña, Alberto, et al.
Publicado: (2018) -
Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
por: Noda-Narita, Shoko, et al.
Publicado: (2019) -
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2020) -
Trastuzumab emtansine: mechanisms of action and drug resistance
por: Barok, Mark, et al.
Publicado: (2014)